The <i>EBF1-PDGFRB</i> T681I mutation is highly resistant to imatinib and dasatinib <i>in vitro</i> and detectable in clinical samples prior to treatment

• Thai Hoa Tran,
• Jonathan V. Nguyen,
• Adrian Stecula,
• Jon Akutagawa,
• Anthony V. Moorman,
• Benjamin S. Braun,
• Andrej Sali,
• Charles G. Mullighan,
• Neil P. Shah,
• Yunfeng Dai,
• Meenakshi Devidas,
• Kathryn G. Roberts,
• Catherine C. Smith,
• Mignon L. Loh

Affiliations

Thai Hoa Tran

Division of Pediatric Hematology-Oncology, Charles-Bruneau Cancer Center, CHU Sainte-Justine, University of Montreal, Montreal, QC, Canada; Department of Pediatrics, Benioff Children’s Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

Jonathan V. Nguyen

Department of Pediatrics, Benioff Children’s Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

Adrian Stecula

Department of Bioengineering and Therapeutic Sciences, Department of Pharmaceutical Chemistry, California Institute for Quantitative Biosciences, University of California, San Francisco, San Francisco, CA

Jon Akutagawa

Department of Pediatrics, Benioff Children’s Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

Anthony V. Moorman

Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne

Benjamin S. Braun

Department of Pediatrics, Benioff Children’s Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

Andrej Sali

Department of Bioengineering and Therapeutic Sciences, Department of Pharmaceutical Chemistry, California Institute for Quantitative Biosciences, University of California, San Francisco, San Francisco, CA

Charles G. Mullighan

Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN

Neil P. Shah

Division of Hematology-Oncology and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

Yunfeng Dai

Department of Biostatistics, College of Medicine and Public Health and Health Professions, University of Florida, Gainesville, FL

Meenakshi Devidas

Department of Global Pediatric Medicine, St. Jude Children’s Research Hospital, Memphis, TN

Kathryn G. Roberts

Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN

Catherine C. Smith

Division of Hematology-Oncology and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

Mignon L. Loh

Department of Pediatrics, Benioff Children’s Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA